PODD Stock Recent News
PODD LATEST HEADLINES
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.
Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Despite Extreme volatility, these five stocks have provided more than 4% returns past month. These are: SFM, UNH, SRAD, GME, PODD.
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Rela.
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections.
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.